Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 11 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 11833210

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted

  2. US 11834436

    Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted

  3. US 11833160

    Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases

    UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted

  4. US 11834515

    Macrocyclic compounds as proteasome inhibitors

    Tri-Institutional Therapeutics Discovery Institute, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted

  5. US 2023381101

    AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Nov 30, 2023 · Expires Nov 25, 2043

    granted

  6. US 11826408

    CD200 inhibitors and methods of use thereof

    Regents of the University of Minnesota · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted

  7. US 11827637

    Azaindole derivatives and their use as ERK kinase inhibitors

    AGV Discovery · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted

  8. US 11826315

    STAT3 inhibitors

    Tvardi Therapeutics, Inc. · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted

  9. US 11820982

    Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted

  10. US 11820775

    Pyrrolopyrimidine ITK inhibitors

    Aclaris Therapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted

  11. US 11813257

    Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors

    Disc Medicine, Inc. · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted

  12. US 11813267

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted

  13. US 11807646

    4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)

    ALMAC DISCOVERY LIMITED · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  14. US 11807658

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  15. US 11807605

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  16. US 11807649

    Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

    EnLiven Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  17. US 11802110

    2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase

    Oxford Drug Design Limited · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  18. US 11793855

    TFPI inhibitors and methods of use

    Takeda Pharmaceutical Company Limited · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted

  19. US 11787762

    Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

    Arcus Biosciences, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted

  20. US 11787796

    Plasma Kallikrein inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted

  21. US 11780837

    CXCR4 inhibitors and uses thereof

    X4 Pharmaceuticals, Inc. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted

  22. US 11780821

    Inhibitors of fibroblast activation protein

    PRAXIS BIOTECH LLC · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted

  23. US 11780845

    FGFR inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted

  24. US 11773393

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.